Use of a urine anastrozole assay to determine treatment discontinuation among women with hormone-sensitive breast cancer: a pilot study
- PMID: 23277771
- PMCID: PMC3439234
- DOI: 10.1200/JOP.2011.000487
Use of a urine anastrozole assay to determine treatment discontinuation among women with hormone-sensitive breast cancer: a pilot study
Abstract
Purpose: Multiple studies have shown that adherence to adjuvant hormonal therapy in women with breast cancer is suboptimal. Measurements of compliance with self-report, pill counts, and/or pharmacy records are susceptible to bias. We assessed the feasibility of using a urine anastrozole assay as an objective biomarker of nonadherence to anastrozole treatment.
Patients and methods: We recruited consecutive postmenopausal women, age ≥ 18 years, with hormone-sensitive nonmetastatic breast cancer who were prescribed anastrozole at least 3 months before enrollment. Each completed a short survey to gather information on demographics, anastrozole compliance history, and self-reported medication history, tumor characteristics, and treatment received. A single, random 15-mL urine sample was collected and tested for the presence of anastrozole using a previously validated assay. Patients were told they were part of a study to determine if anastrozole could be detected in the urine.
Results: Among 96 participants, mean age was 63.7 years (range, 51 to 70 years). The population was diverse, with 56.5% white, 57.6% US born, 59.8% unemployed, and 56.6% college educated. Prior treatment included chemotherapy (50%) and/or radiotherapy (58.7%). Mean duration of anastrozole treatment was 2.2 years (standard deviation, 1.6). Four participants reported nonadherence and declined to submit urine samples, and two had no detectable level of anastrozole (six of 96; 6.3%). Detectable levels among adherent women ranged from 49.3 to 632.8 ng/mL.
Conclusion: We demonstrated that collection of urine to measure anastrozole levels is feasible and reliable. Identifying biomarkers to measure adherence is critical for studies investigating interventions to improve hormonal therapy compliance.
Figures
Similar articles
-
Adherence to adjuvant endocrine therapy in postmenopausal women with breast cancer.Ann Oncol. 2009 Mar;20(3):431-6. doi: 10.1093/annonc/mdn646. Epub 2009 Jan 15. Ann Oncol. 2009. PMID: 19150950
-
Identification of the aromatase inhibitors anastrozole and exemestane in human urine using liquid chromatography/tandem mass spectrometry.Rapid Commun Mass Spectrom. 2006;20(12):1954-62. doi: 10.1002/rcm.2545. Rapid Commun Mass Spectrom. 2006. PMID: 16715475
-
Extended adjuvant therapy with anastrozole among postmenopausal breast cancer patients: results from the randomized Austrian Breast and Colorectal Cancer Study Group Trial 6a.J Natl Cancer Inst. 2007 Dec 19;99(24):1845-53. doi: 10.1093/jnci/djm246. Epub 2007 Dec 11. J Natl Cancer Inst. 2007. PMID: 18073378 Clinical Trial.
-
Fulvestrant: a review of its use in hormone receptor-positive metastatic breast cancer in postmenopausal women with disease progression following antiestrogen therapy.Drugs. 2004;64(6):633-48. doi: 10.2165/00003495-200464060-00009. Drugs. 2004. PMID: 15018596 Review.
-
Anastrozole: a review of its use in postmenopausal women with early-stage breast cancer.Drugs. 2008;68(9):1319-40. doi: 10.2165/00003495-200868090-00007. Drugs. 2008. PMID: 18547136 Review.
Cited by
-
The use of mass spectrometry for analysing metabolite biomarkers in epidemiology: methodological and statistical considerations for application to large numbers of biological samples.Eur J Epidemiol. 2016 Aug;31(8):717-33. doi: 10.1007/s10654-016-0166-2. Epub 2016 May 26. Eur J Epidemiol. 2016. PMID: 27230258 Review.
-
Interventions to improve endocrine therapy adherence in breast cancer survivors: what is the evidence?J Cancer Surviv. 2018 Jun;12(3):348-356. doi: 10.1007/s11764-017-0674-4. Epub 2018 Feb 2. J Cancer Surviv. 2018. PMID: 29396760 Review.
-
Patient-Reported Outcomes and Long-Term Nonadherence to Aromatase Inhibitors.J Natl Cancer Inst. 2021 Aug 2;113(8):989-996. doi: 10.1093/jnci/djab022. J Natl Cancer Inst. 2021. PMID: 33629114 Free PMC article. Clinical Trial.
-
Oral cancer chemotherapy adherence and adherence assessment tools: a report from North Central Cancer Group Trial N0747 and a systematic review of the literature.J Cancer Educ. 2013 Dec;28(4):770-6. doi: 10.1007/s13187-013-0511-z. J Cancer Educ. 2013. PMID: 23872949 Free PMC article.
-
Randomized Trial of Text Messaging to Reduce Early Discontinuation of Adjuvant Aromatase Inhibitor Therapy in Women With Early-Stage Breast Cancer: SWOG S1105.J Clin Oncol. 2020 Jul 1;38(19):2122-2129. doi: 10.1200/JCO.19.02699. Epub 2020 May 5. J Clin Oncol. 2020. PMID: 32369401 Free PMC article. Clinical Trial.
References
-
- Howell A, Cuzick J, Baum M, et al. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet. 2005;365:60–62. - PubMed
-
- Early Breast Cancer Trialists' Collaborative Group (EBCTCG) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials. Lancet. 2005;365:1687–1717. - PubMed
-
- Bickell NA, LePar F, Wang JJ, et al. Lost opportunities: Physicians' reasons and disparities in breast cancer treatment. J Clin Oncol. 2007;25:2516–2521. - PubMed
-
- Bickell NA, Wang JJ, Oluwole S, et al. Missed opportunities: Racial disparities in adjuvant breast cancer treatment. J Clin Oncol. 2006;24:1357–1362. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical